[go: up one dir, main page]

SI1305041T1 - Zdravilo za imunoterapijo malignih tumorjev - Google Patents

Zdravilo za imunoterapijo malignih tumorjev

Info

Publication number
SI1305041T1
SI1305041T1 SI200130618T SI200130618T SI1305041T1 SI 1305041 T1 SI1305041 T1 SI 1305041T1 SI 200130618 T SI200130618 T SI 200130618T SI 200130618 T SI200130618 T SI 200130618T SI 1305041 T1 SI1305041 T1 SI 1305041T1
Authority
SI
Slovenia
Prior art keywords
medicament
immunotherapy
malignant tumours
tumors
relates
Prior art date
Application number
SI200130618T
Other languages
English (en)
Inventor
Claudia Ulbrich
Klaus-Dieter Rockensuess
Armin Grossmann
Original Assignee
Liponova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Ag filed Critical Liponova Ag
Publication of SI1305041T1 publication Critical patent/SI1305041T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200130618T 2000-07-28 2001-07-21 Zdravilo za imunoterapijo malignih tumorjev SI1305041T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (1)

Publication Number Publication Date
SI1305041T1 true SI1305041T1 (sl) 2006-12-31

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130618T SI1305041T1 (sl) 2000-07-28 2001-07-21 Zdravilo za imunoterapijo malignih tumorjev

Country Status (20)

Country Link
US (2) US20030129206A1 (sl)
EP (1) EP1305041B1 (sl)
JP (1) JP2004505058A (sl)
AT (1) ATE330626T1 (sl)
AU (1) AU2001279775A1 (sl)
BG (1) BG107482A (sl)
CA (1) CA2417374A1 (sl)
CY (1) CY1105179T1 (sl)
CZ (1) CZ299669B6 (sl)
DE (1) DE50110274D1 (sl)
DK (1) DK1305041T3 (sl)
ES (1) ES2267800T3 (sl)
HK (1) HK1055562A1 (sl)
HU (1) HUP0300772A3 (sl)
NO (1) NO20030420L (sl)
PL (1) PL358675A1 (sl)
PT (1) PT1305041E (sl)
SI (1) SI1305041T1 (sl)
SK (1) SK822003A3 (sl)
WO (1) WO2002009745A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
RU2324493C2 (ru) * 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
CN107412755A (zh) 2009-07-02 2017-12-01 Ith免疫治疗控股公司 基于外泌体的癌症治疗
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
EP3425400B1 (en) 2017-07-05 2022-01-26 VCC Medical Deutschland GmbH Method for manufacturing a tumor vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
JP2002504322A (ja) * 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
JP2002510642A (ja) * 1998-04-02 2002-04-09 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア ヒト患者における抗原提示細胞および抗腫瘍応答の増強法
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
WO2002009745A1 (de) 2002-02-07
ATE330626T1 (de) 2006-07-15
HK1055562A1 (en) 2004-01-16
PL358675A1 (en) 2004-08-09
HUP0300772A2 (en) 2003-08-28
CZ299669B6 (cs) 2008-10-08
NO20030420D0 (no) 2003-01-27
DK1305041T3 (da) 2006-10-23
SK822003A3 (en) 2004-05-04
EP1305041A1 (de) 2003-05-02
EP1305041B1 (de) 2006-06-21
NO20030420L (no) 2003-01-27
JP2004505058A (ja) 2004-02-19
US20070134275A1 (en) 2007-06-14
US20030129206A1 (en) 2003-07-10
HUP0300772A3 (en) 2005-11-28
DE50110274D1 (de) 2006-08-03
CZ2003179A3 (cs) 2004-01-14
BG107482A (bg) 2003-11-28
CY1105179T1 (el) 2010-03-03
CA2417374A1 (en) 2003-01-27
ES2267800T3 (es) 2007-03-16
PT1305041E (pt) 2006-09-29
AU2001279775A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
YU23202A (sh) Lekovi za tretman malignih tumora
EP1468014A4 (en) COMPOSITIONS AND METHODS FOR WT1-SPECIFIC IMMUNOTHERAPY
IL148782A0 (en) Drugs for the treatment of malignant tumours
SI1255537T1 (sl) Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
MY136520A (en) Novel compounds
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
SE9901875D0 (sv) Novel compounds
MY128924A (en) Novel compounds
HK1040983A1 (en) Quinones for treatment of diseases.
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
MXPA05009480A (es) Metodos y composiciones para la sintesis enzimatica de gangliosidos.
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
BR0015597A (pt) Uso de anticorpos como vacinas
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
TW200504051A (en) Novel acridine derivatives and their use as medicaments
MX2010004332A (es) Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer.
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
WO2003035104A3 (en) Compositions and methods for selected tumor treatment
AU2002352011A1 (en) Immunogenic alk (anaplastic lymphoma kinase) peptides
IL159469A0 (en) Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours
TW200621270A (en) Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold